TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05879250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo routine radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo routine radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAT3 Inhibitor WP1066
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAT3 Inhibitor WP1066
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo removal or biopsy of tumor
Study: NCT05003310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Stimulation
Description: Stimulation will be turned ON and applied during each day of the period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Stimulation
Description: Stimulation will be turned ON and applied during each day of the period.

Intervention type: DEVICE
Group type: OTHER
Intervention: Active Stimulation
Description: Stimulation will be turned ON and applied during each day of the period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Stimulation
Description: Stimulation will be turned ON and applied during each day of the period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Stimulation
Description: Stimulation will be turned ON and applied during each day of the period.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham stimulation will be provided during the period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib (2 mg) is administered daily during the period.

Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib
Description: Baricitinib (2 mg) is administered daily during the period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib (2 mg) is administered daily during the period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Treatment
Description: Stable dose of standard background treatment (e.g., csDMARD therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Treatment
Description: Stable dose of standard background treatment (e.g., csDMARD therapy)

Intervention type: DRUG
Group type: OTHER
Intervention: Background Treatment
Description: Stable dose of standard background treatment (e.g., csDMARD therapy)

Intervention type: DRUG
Group type: OTHER
Intervention: Background Treatment
Description: Stable dose of standard background treatment (e.g., csDMARD therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Treatment
Description: Stable dose of standard background treatment (e.g., csDMARD therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Treatment
Description: Stable dose of standard background treatment (e.g., csDMARD therapy)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Background Treatment
Description: Stable dose of standard background treatment (e.g., csDMARD therapy)
Study: NCT05729100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate-electrolyte solution
Description: Oral solution containing 10% glucose and electrolyte (in every 300 ml of fluid (contains 30 gr dextrose, 150 mg Natrium chloride, 366 mg Kalium chloride)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Standard clear fluid (water)
Study: NCT05586971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigulixostat
Description: Xanthine Oxidase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigulixostat
Description: Xanthine Oxidase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigulixostat
Description: Xanthine Oxidase Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Xanthine Oxidase Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT06573606

Intervention type: DEVICE
Intervention: CX-HA and CS
Description: Sterile Isotonic ophthalmic solution
Study: NCT04870385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-week prevention program
Description: Online modular psychological prevention program featuring integrated elements of Islamic spirituality and Acceptance and Commitment Therapy (ACT).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Control group waitlisted to receive prevention program after completion of final data collection.
Study: NCT06383910

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Square Stepping Exercise
Description: The exercise is performed on a thin exercise mat divided into 40 small squares. Participants are shown specific step patterns on this mat and are instructed to repeat the same step pattern until the end of the exercise mat. Once a pattern is completed on the exercise mat, its mirror-image pattern is also performed. The basic pattern is repeated 3-5 times, followed by the same number of repetitions for the mirror-image pattern. However, if participants struggle with the pattern, it is repeated until they learn it. Individuals execute the demonstrated pattern on the exercise mat and return to the beginning of the mat after completing it.
Study: NCT05297370

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mixed and match Intervention
Description: Participants will receive a brief 15-minute counselling session based on the 5A's' and '5R's' models by our trained research assistant. Participants will be able to choose their smoking cessation treatment options from our menu.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants in the control group will receive a self-help quitting leaflet issued by the TACO
Study: NCT06029374

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Treatment
Description: Patients receiving buddy taping for fingers IV and V and an elastic bandage in terms of a functional treatment. Duration of bandage treatment is determined with 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm Cast and Finger Splint
Description: Patients receiving reduction of fractured finger and subsequent customization of a forearm cast with a finger splint. Duration of cast treatment is determined with 4 weeks.
Study: NCT05675904

Intervention type: PROCEDURE
Intervention: Colon oncological resection
Description: Scheduled colon cancer surgery

Intervention type: PROCEDURE
Intervention: Colon oncological resection
Description: Scheduled colon cancer surgery
Study: NCT06239493

Intervention type: DIAGNOSTIC_TEST
Intervention: IVUS Guided
Description: Those already undergoing an IVUS guided percutaneous vascular intervention
Study: NCT00722774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H2N2 1960 AA ca recombinant vaccine
Description: Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
Study: NCT05330156

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral resection of the prostate
Description: - After an initial cysto-urethroscopy assessment done, Transurethral resection of the prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral enucleation of prostate
Description: After an initial cysto-urethroscopy assessment done, transurethral enucleation of prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
Study: NCT05188040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercises
Description: Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
Study: NCT04836962

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2cc of normal saline is administered to patient instead of dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone is administered 0.5mg/kg (up to 10mg) which is diluted with normal saline to make a total of 2cc.
Study: NCT05101746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide (NO) 20 part per million (ppm)
Description: Nitric oxide will be mixed into the gas flow of the cardiopulmonary bypass (CPB) oxygenator, which will be kept at 1-3 L/min to allow for the desired NO delivery rate. NO levels will be maintained at 20ppm using a NO delivery system (INOmax, Mallinckrodt).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care cardiopulmonary bypass
Description: Cardiopulmonary bypass (CPB) will be performed using the departmental guidelines and standards. CPB will be performed using in a nonpulsatile flow with the System 1 Heart Lung Machine (Terumo Cardiovascular Systems, Ann Arbor, Mich). The maximum perfusion flow will be 200 ml/kg/minute. Blood pressure management will be selected based on the patient age and procedure. Temperature management will be to cool the patient 32 celsius (C).
Study: NCT04437290

Intervention type: DRUG
Intervention: investigational radiotracer [18F]MK6240
Description: Brain PET scan
Study: NCT05139771

Intervention type: DEVICE
Group type: OTHER
Intervention: THE ENDOART® IMPLANTATION (Artificial Endothelial layer)
Description: Implantation of EndoArt® is similar to other anterior segment surgical procedures such as DSAEK/DMEK.
Study: NCT05263050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib initiated at 40 mg daily. Dose-escalate or de-escalate based on pre-specified criteria and at set dosing schedules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib initiated at 40 mg daily. Dose-escalate or de-escalate based on pre-specified criteria and at set dosing schedules
Study: NCT05107284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-checkup to go
Description: The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: e-checkup to go
Description: The e-checkup to go alcohol program is designed to motivate individuals to reduce their alcohol consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed feedback booster
Description: Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm.
Study: NCT05263050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab injection is to be administered as an IV infusion at a dose of 480 mg on day 1 of each cycle
Study: NCT05555459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operation
Description: Bone fixation operation in foot or ankle area using bioabsorbable headless screw/s
Study: NCT04946968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Dacomitinib
Description: All subjects will receive the open-label Dacomitinib as tablets for oral self-administration on a continuous daily basis at a dose of 30 mg for one cycle. For subjects eligible for dose titration after Cycle 1, and after shared patient and investigator decision, these subjects will receive Dacomitinib 45 mg orally on a continuous daily basis.
Study: NCT05242991

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation therapy
Description: Light therapy for the management of oral side effects related to radiotherapy, mainly in the decrease of oral mucositis (OM) rates and OM severity, healing of OM ulcers and pain relief.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation therapy
Description: Light therapy for the management of oral side effects related to radiotherapy, mainly in the decrease of oral mucositis (OM) rates and OM severity, healing of OM ulcers and pain relief.
Study: NCT05323318

Intervention type: OTHER
Intervention: Neuropsychological Sequelae
Description: Neuropsychological Sequelae after SARS-CoV-2 symtomatic infection
Study: NCT04958109

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: Administration of a 75 gm oral glucose tolerance test

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Administration of a 75 gm oral glucose tolerance test

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin
Description: Intravenous administration of kisspeptin 112-121 x 16 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of Placebo 16 hours
Study: NCT05625958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cilioscleral Interposition Device
Description: Surgical placement of SV22 cilioscleral interposition device in the supraciliary space
Study: NCT05099042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommendations and re-orientation towards appropriate physical, mental, and social health ressources
Description: Resources recommendations and interventions curated to the needs of the EP such as refering them to a social activity for socially isolated EP.
Study: NCT04728529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: USSM protocol
Description: In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical and USCOM examination. If any improvement of clinical sign and normal SVI, CI, SVR, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by USCOM.~The therapeutic goal of USCOM: SVI 30-60 mL/m2, CI 3.3-6.0 L/minute/m2, and SVRI 800-1600 d.s/cm5/m2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACCM protocol
Description: In the initial step, all subjects will receive emergency management: oxygen support, vascular access, and fluid therapy. Doppler ultrasonography by Ultrasound Cardiac Output Monitoring (USCOM) is also performed to record initial stroke volume (SV), cardiac index (CI), and systemic vascular resistance (SVR). The initial fluid resuscitation is 20 mL/kg body weight, then the response measured by clinical. If any improvement of clinical sign, intervention will be stopped. In contrary, if shock persist, subsequent fluid resuscitation and/or vasoactive therapy will be administered, guided by clinical parameter.
Study: NCT06111456

Intervention type: OTHER
Intervention: Questionnaire
Description: Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.

Intervention type: OTHER
Intervention: Questionnaire
Description: Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic.

Intervention type: OTHER
Intervention: Interview
Description: Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway

Intervention type: OTHER
Intervention: Interview
Description: Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
Study: NCT06496633

Intervention type: PROCEDURE
Intervention: Percutaneous Intramyocardial Septal Radiofrequency Ablation
Description: PIMSRA procedure represents a significant breakthrough in the treatment of HOCM patients, as it uses a unique transmyocardial approach to directly and precisely insert a radiofrequency electrode needle into the hypertrophied IVS for targeted ablation
Study: NCT05773976

Intervention type: DEVICE
Group type: OTHER
Intervention: Afomill Refreshing Soothing, Afomill Anti-redness Eye Drops, Iridil
Description: At baseline visit (V0), as per clinical practice, only one of the below reported IPs products can be dispensed to the enrolled subject, depending on investigator clinical evaluation and decision:~* Afomill Refreshing Soothing~* Afomill Anti-redness Eye Drops~* Iridil
Study: NCT05876546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid bandage
Description: The liquid bandage will be applied through a patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The liquid bandage will be applied again to the participants' back, in a naive area and removed after 48 hours.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Saline Solution
Description: The saline solution will be applied via patch test to the participants' backs for 3 consecutive weeks, with 3 weekly applications. Afterwards, there will be a rest period of between 10 and 15 days. The saline solution will be applied again to the participants' back, in a naive area and removed after 48 hours.
Study: NCT04730050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TT-01025-CL
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-01025-CL
Description: Oral tablet
Study: NCT05265611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low intensity psychosocial intervention - Problem Management Plus (PM+)
Description: Syrian refugee young adults will be trained to implement Problem Management Plus (PM+). PM+ is a low-intensity mental health intervention, developed by WHO, and delivered by non-specialized CMHW. It is a transdiagnostic treatment approach that includes four evidence-based problem solving and behavioral treatment techniques: managing stress, managing problems, get going/get doing, and social support. These strategies are implemented over five weekly sessions, of 90 minutes each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tutoring
Description: Young adults will be trained to tutor students in elementary school.
Study: NCT06111456

Intervention type: OTHER
Intervention: Interview
Description: Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway
Study: NCT04984850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral chemotherapy information and support
Description: Multimodal intervention : (1) handouts and videos presenting information and supportive resources for common oral chemotherapy related issues, (2) phone call(s) from a nurse in oncology, and (3) e-reminders to take medication. The intervention will be available to experimental group participants on mobile platform.
Study: NCT05365893

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paricalcitol, Hydroxychloroquine, Losartan
Description: Paricalcitol 25 mcg IV administered M-W-F Hydroxychloroquine 600 mg PO BID Losartan 50 mg PO daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant therapy and surgery only (Control)
Description: Control arm These patients will proceed to surgery at completion of neoadjuvant therapy.
Study: NCT05770479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules
Description: ME-CCT is a traditionally a manualized group-based behavioral intervention (8 weeks, 2 hours per week) designed to improve cognitive and everyday functioning in patients with MCI. Our booster modules will be shortened and distilled from ME-CCT using the IM Adapt protocol (and thus will not be new information but rather 'reminder' content) for a personalized four-session sequence of booster training targeted toward specific everyday functional needs of individual participants.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: Treatment for MCI is generally managed by Primary Care or Neurology. Participants will continue to receive their usual care with their current providers. With no effective pharmacological treatment known for persons with MCI, providers tend to focus on encouraging a healthy lifestyle, prevention and management of modifiable risk factors for cognitive impairment, and treatment of behavioral and psychiatric symptoms.